Literature DB >> 22239408

Toll-like receptor (TLR)-7 and -8 modulatory activities of dimeric imidazoquinolines.

Nikunj M Shukla1, Cole A Mutz, Subbalakshmi S Malladi, Hemamali J Warshakoon, Rajalakshmi Balakrishna, Sunil A David.   

Abstract

Toll-like receptors (TLRs) are pattern recognition receptors that recognize specific molecular patterns present in molecules that are broadly shared by pathogens but are structurally distinct from host molecules. The TLR7-agonistic imidazoquinolines are of interest as vaccine adjuvants given their ability to induce pronounced Th1-skewed humoral responses. Minor modifications on the imidazoquinoline scaffold result in TLR7-antagonistic compounds which may be of value in addressing innate immune activation-driven immune exhaustion observed in HIV. We describe the syntheses and evaluation of TLR7 and TLR8 modulatory activities of dimeric constructs of imidazoquinoline linked at the C2, C4, C8, and N(1)-aryl positions. Dimers linked at the C4, C8, and N(1)-aryl positions were agonistic at TLR7; only the N(1)-aryl dimer with a 12-carbon linker was dual TLR7/8 agonistic. Dimers linked at C2 position showed antagonistic activities at TLR7 and TLR8; the C2 dimer with a propylene spacer was maximally antagonistic at both TLR7 and TLR8.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22239408      PMCID: PMC3276691          DOI: 10.1021/jm2010207

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  41 in total

Review 1.  LPS, dsRNA and the interferon bridge to adaptive immune responses: Trif, Tram, and other TIR adaptor proteins.

Authors:  Kasper Hoebe; Bruce Beutler
Journal:  J Endotoxin Res       Date:  2004

2.  Synthesis and structure-activity-relationships of 1H-imidazo[4,5-c]quinolines that induce interferon production.

Authors:  John F Gerster; Kyle J Lindstrom; Richard L Miller; Mark A Tomai; Woubalem Birmachu; Shannon N Bomersine; Shiela J Gibson; Linda M Imbertson; Joel R Jacobson; Roy T Knafla; Peter V Maye; Nickolas Nikolaides; Folakemi Y Oneyemi; Gwen J Parkhurst; Sharon E Pecore; Michael J Reiter; Lisa S Scribner; Tracy L Testerman; Natalie J Thompson; Tammy L Wagner; Charles E Weeks; Jean-Denis Andre; Daniel Lagain; Yvon Bastard; Michel Lupu
Journal:  J Med Chem       Date:  2005-05-19       Impact factor: 7.446

3.  Synthetic TLR agonists reveal functional differences between human TLR7 and TLR8.

Authors:  Keith B Gorden; Kevin S Gorski; Sheila J Gibson; Ross M Kedl; William C Kieper; Xiaohong Qiu; Mark A Tomai; Sefik S Alkan; John P Vasilakos
Journal:  J Immunol       Date:  2005-02-01       Impact factor: 5.422

Review 4.  Transcriptional signaling by double-stranded RNA: role of TLR3.

Authors:  Ganes C Sen; Saumendra N Sarkar
Journal:  Cytokine Growth Factor Rev       Date:  2005-02       Impact factor: 7.638

5.  Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway.

Authors:  Hiroaki Hemmi; Tsuneyasu Kaisho; Osamu Takeuchi; Shintaro Sato; Hideki Sanjo; Katsuaki Hoshino; Takao Horiuchi; Hideyuki Tomizawa; Kiyoshi Takeda; Shizuo Akira
Journal:  Nat Immunol       Date:  2002-01-22       Impact factor: 25.606

6.  Synthetic double-stranded RNA poly(I:C) combined with mucosal vaccine protects against influenza virus infection.

Authors:  Takeshi Ichinohe; Izumi Watanabe; Satoshi Ito; Hideki Fujii; Masami Moriyama; Shin-Ichi Tamura; Hidehiro Takahashi; Hirofumi Sawa; Joe Chiba; Takeshi Kurata; Tetsutaro Sata; Hideki Hasegawa
Journal:  J Virol       Date:  2005-03       Impact factor: 5.103

7.  Molecular basis for the immunostimulatory activity of guanine nucleoside analogs: activation of Toll-like receptor 7.

Authors:  Jongdae Lee; Tsung-Hsien Chuang; Vanessa Redecke; Liping She; Paula M Pitha; Dennis A Carson; Eyal Raz; Howard B Cottam
Journal:  Proc Natl Acad Sci U S A       Date:  2003-05-08       Impact factor: 11.205

Review 8.  Dendritic cell (DC) based therapy for cervical cancer: use of DC pulsed with tumour lysate and matured with a novel synthetic clinically non-toxic double stranded RNA analogue poly [I]:poly [C(12)U] (Ampligen R).

Authors:  M Adams; H Navabi; B Jasani; S Man; A Fiander; A S Evans; C Donninger; M Mason
Journal:  Vaccine       Date:  2003-01-30       Impact factor: 3.641

9.  Modified polyriboinosinic-polyribocytidylic acid, an immunological adjuvant.

Authors:  W E Houston; C L Crabbs; E L Stephen; H B Levy
Journal:  Infect Immun       Date:  1976-07       Impact factor: 3.441

Review 10.  Toll-like receptor 3: a link between toll-like receptor, interferon and viruses.

Authors:  Misako Matsumoto; Kenji Funami; Hiroyuki Oshiumi; Tsukasa Seya
Journal:  Microbiol Immunol       Date:  2004       Impact factor: 1.955

View more
  24 in total

1.  Covalent modification of cell surfaces with TLR agonists improves & directs immune stimulation.

Authors:  Janine K Tom; Rock J Mancini; Aaron P Esser-Kahn
Journal:  Chem Commun (Camb)       Date:  2013-10-25       Impact factor: 6.222

Review 2.  Beyond antigens and adjuvants: formulating future vaccines.

Authors:  Tyson J Moyer; Andrew C Zmolek; Darrell J Irvine
Journal:  J Clin Invest       Date:  2016-03-01       Impact factor: 14.808

3.  Immune Response Modulation of Conjugated Agonists with Changing Linker Length.

Authors:  Keun Ah Ryu; Katarzyna Slowinska; Troy Moore; Aaron Esser-Kahn
Journal:  ACS Chem Biol       Date:  2016-10-25       Impact factor: 5.100

4.  Covalently coupled immunostimulant heterodimers.

Authors:  Rock J Mancini; Janine K Tom; Aaron P Esser-Kahn
Journal:  Angew Chem Int Ed Engl       Date:  2013-11-20       Impact factor: 15.336

5.  Facile syntheses of functionalized toll-like receptor 7 agonists.

Authors:  Babatope Akinbobuyi; Matthew R Byrd; Charles A Chang; Mysa Nguyen; Zacharie J Seifert; Anne-Laure Flamar; Gerard Zurawski; Katherine C Upchurch; SangKon Oh; Stephen H Dempsey; Thomas J Enke; John Le; Hunter J Winstead; José R Boquín; Robert R Kane
Journal:  Tetrahedron Lett       Date:  2015-01-08       Impact factor: 2.415

6.  Toll-like receptor-8 agonistic activities in C2, C4, and C8 modified thiazolo[4,5-c]quinolines.

Authors:  Hari Prasad Kokatla; Euna Yoo; Deepak B Salunke; Diptesh Sil; Cameron F Ng; Rajalakshmi Balakrishna; Subbalakshmi S Malladi; Lauren M Fox; Sunil A David
Journal:  Org Biomol Chem       Date:  2013-02-21       Impact factor: 3.876

7.  Antibacterial activities of Groebke-Blackburn-Bienaymé-derived imidazo[1,2-a]pyridin-3-amines.

Authors:  Nikunj M Shukla; Deepak B Salunke; Euna Yoo; Cole A Mutz; Rajalakshmi Balakrishna; Sunil A David
Journal:  Bioorg Med Chem       Date:  2012-08-08       Impact factor: 3.641

8.  Structure-activity relationships in human Toll-like receptor 8-active 2,3-diamino-furo[2,3-c]pyridines.

Authors:  Deepak B Salunke; Euna Yoo; Nikunj M Shukla; Rajalakshmi Balakrishna; Subbalakshmi S Malladi; Katelyn J Serafin; Victor W Day; Xinkun Wang; Sunil A David
Journal:  J Med Chem       Date:  2012-09-07       Impact factor: 7.446

9.  Exquisite selectivity for human toll-like receptor 8 in substituted furo[2,3-c]quinolines.

Authors:  Hari Prasad Kokatla; Diptesh Sil; Subbalakshmi S Malladi; Rajalakshmi Balakrishna; Alec R Hermanson; Lauren M Fox; Xinkun Wang; Anshuman Dixit; Sunil A David
Journal:  J Med Chem       Date:  2013-08-15       Impact factor: 7.446

Review 10.  Structural evolution of toll-like receptor 7/8 agonists from imidazoquinolines to imidazoles.

Authors:  Deepender Kaushik; Arshpreet Kaur; Nikolai Petrovsky; Deepak B Salunke
Journal:  RSC Med Chem       Date:  2021-05-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.